reports
Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 Febru...
Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Company Release no. 13/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 17 February 2020 Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Today, Veloxis Pharmaceuticals A/S' Extraordinary General Meeting passed the following resolutions: The following persons were elected as members of the Board of Directors: Masaya EtohDaisuke MatsuoMatthew Ryan Dumont The elected board members replace all current membe...
Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmace...
Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Selskabsmeddelelse nr. 12/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 29. januar 2020 Offentliggørelse af Nasdaq Copenhagen A/S' Accept af Veloxis Pharmaceuticals A/S' Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Som meddelt ved selskabsmeddelelse nr. 10/2020 har Veloxis Pharmaceuticals A/S ("Veloxis"), eft...
Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Reques...
Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S Company Release no. 12/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 29 January 2020 Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S As announced in company release no. 10/2020, Veloxis Pharmaceuticals A/S ("Veloxis") has, upon request from Asahi Kasei Pharma Denmark A/S, requested Nasdaq Copenhagen A/S ("Nasdaq Cop...
Notice to Convene Extraordinary General Meeting
Notice to Convene Extraordinary General Meeting Company Announcement no. 11/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 24 January 2020 Notice to Convene Extraordinary General Meeting Upon request from Asahi Kasei Pharma Denmark A/S, the board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 (the "Company"), hereby convenes an extraordinary general meeting in the Company to be held on Monday 17 February 2020 at 12:00 p.m. CET at the offices o...
Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceutical...
Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Selskabsmeddelelse nr. 10/2020 Til: NASDAQ Copenhagen A/S København, Danmark, fredag den 24. januar 2020 Offentliggørelse af Anmodning om Afnotering af Veloxis Pharmaceuticals A/S' Aktier fra Nasdaq Copenhagen A/S Med henvisning til selskabsmeddelelse nr. 9/2020, i hvilken Asahi Kasei Pharma Denmark A/S offentliggjorde sin beslutning om at udnytte sin ret til at gennemføre en tvangsindløsning af aktierne ejet af Vel...
Announcement of Request for Delisting of Veloxis Pharmaceuticals A/S' ...
Announcement of Request for Delisting of Veloxis Pharmaceuticals A/S' Shares from Nasdaq Copenhagen Company Release no. 10/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Announcement of Request for Delisting of Veloxis Pharmaceuticals A/S' Shares from Nasdaq Copenhagen Following company release no. 9/2020, in which Asahi Kasei Pharma Denmark A/S announced its decision to initiate a compulsory acquisition of the shares held by Veloxis Pharmaceutical A/S' ("Veloxis'") remain...
Meddelelse om Tvangsindløsning til Aktionærerne i Veloxis Pharmaceut...
Meddelelse om Tvangsindløsning til Aktionærerne i Veloxis Pharmaceuticals A/S Selskabsmeddelelse nr. 9/2020 Til: NASDAQ Copenhagen A/S København, Danmark, fredag den 24. januar 2020 Meddelelse om Tvangsindløsning til Aktionærerne i Veloxis Pharmaceuticals A/S Asahi Kasei Pharma Denmark A/S har fremsendt meddelelse om tvangsindløsning til aktionærerne i Veloxis Pharmaceuticals A/S ("Veloxis") i overensstemmelse med selskabslovens §§ 70-72. Asahi Kasei Pharma Denmark A/S' meddelelse om tvangsindløsning til aktionærerne i Veloxis er ved...
Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharma...
Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S Company Release no. 9/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S Pursuant to Sections 70-72 of the Danish Companies Act, Asahi Kasei Pharma Denmark A/S today announces its notice on compulsory acquisition to the shareholders of Veloxis Pharmaceuticals A/S ("Veloxis"). Reference is made to Asahi Kasei Pharma Denmark A/S' anno...
Veloxis Pharmaceuticals A/S: Offentliggørelse af Storaktionærmeddele...
Veloxis Pharmaceuticals A/S: Offentliggørelse af Storaktionærmeddelelser Selskabsmeddelelse nr. 8/2020 Til: NASDAQ Copenhagen A/S København, Danmark, fredag den 24. januar 2020 Veloxis Pharmaceuticals A/S: Offentliggørelse af Storaktionærmeddelelser Veloxis Pharmaceuticals A/S (OMX: VELO) ("Veloxis") offentliggør hermed selskabets modtagelse af storaktionærmeddelelser i henhold til kapitel 7 i lovbekendtgørelse nr. 931 af 6. september 2019 Kapitalmarkedsloven ("Kapitalmarkedsloven"), med senere ændringer. Storaktionærmeddelels...
Veloxis Pharmaceuticals A/S: Major Shareholder Notifications
Veloxis Pharmaceuticals A/S: Major Shareholder Notifications Company Release no. 8/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Veloxis Pharmaceuticals A/S: Major Shareholder Notifications Veloxis Pharmaceuticals A/S (OMX: VELO) ("Veloxis") hereby announces that it has received major shareholder notifications pursuant to chapter 7 of Consolidated act no. 931 of 06 September 2019 on Capital Markets, as amended (the "Capital Markets Act"). Pursuant to section 30 of the Capital Markets Act, these major shar...
Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma ...
Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark's Exercise of Warrants Acquired under the Public Tender Offer Company Release no. 7/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Thursday 23 January 2020 Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark's Exercise of Warrants Acquired under the Public Tender Offer On 17 January 2020, Asahi Kasei Pharma Denmark A/S ("Asahi Kasei Pharma Denmark") announced the final result of the recommended conditional voluntary ...
Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma ...
Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma Denmarks Udnyttelse af Warrants Erhvervet under det Offentlige Købstilbud Selskabsmeddelelse nr. 7/2020 Til: NASDAQ Copenhagen A/S København, Danmark, torsdag den 23. januar 2020 Veloxis Forhøjer Aktiekapitalen i forbindelse med Asahi Kasei Pharma Denmarks Udnyttelse af Warrants Erhvervet under det Offentlige Købstilbud Den 17. januar 2020 offentliggjorde Asahi Kasei Pharma Denmark A/S ("Asahi Kasei Pharma Denmark") det endelige resultat af det anbefalede...
Asahi Kasei Pharma Denmark A/S Announces the Final Result of the Volun...
Asahi Kasei Pharma Denmark A/S Announces the Final Result of the Voluntary Public Tender Offer Company Release no. 6/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 17 January 2020 Asahi Kasei Pharma Denmark A/S Announces the Final Result of the Voluntary Public Tender Offer Asahi Kasei Pharma Denmark A/S, which on 15 January 2020 announced the preliminary result of the voluntary public tender offer for the shares and warrants in Veloxis Pharmaceuticals A/S, today announces the final result of the voluntary public t...
Asahi Kasei Pharma Denmark A/S meddeler det endelige resultat det friv...
Asahi Kasei Pharma Denmark A/S meddeler det endelige resultat det frivillige offentlige købstilbud Selskabsmeddelelse nr. 6/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 17. januar 2020 Asahi Kasei Pharma Denmark A/S meddeler det endelige resultat det frivillige offentlige købstilbud Asahi Kasei Pharma Denmark A/S, som den 15. januar 2020 offentliggjorde det foreløbige resultat af det frivillige offentlige købstilbud på aktier og warrants i Veloxis Pharmaceuticals A/S, offentliggør i dag det endelige resultat af det...
Veloxis Pharmaceuticals: Reporting of Managers' and Closely Associated...
Veloxis Pharmaceuticals: Reporting of Managers' and Closely Associated Persons' Transactions in Veloxis-Shares and Financial Instruments Linked Hereto Company Release no. 5/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 15 January 2020 Veloxis Pharmaceuticals: Reporting of Managers' and Closely Associated Persons' Transactions in Veloxis-Shares and Financial Instruments Linked Hereto Today, Veloxis Pharmaceuticals A/S (OMX: VELO) ("Veloxis") announces the attached reporting of transactions in Veloxis-shares and financial instruments l...
Veloxis Pharmaceuticals: Offentliggørelse af ledende medarbejderes og...
Veloxis Pharmaceuticals: Offentliggørelse af ledende medarbejderes og personer, der er nært knyttet til ledende medarbejderes transaktioner med Veloxis-aktier og finansielle instrumenter forbundet hermed Selskabsmeddelelse nr. 5/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 15. januar 2020 Veloxis Pharmaceuticals: Offentliggørelse af ledende medarbejderes og personer, der er nært knyttet til ledende medarbejderes transaktioner med Veloxis-aktier og finansielle instrumenter forbundet hermed I overensstemmelse med artikel ...
Veloxis Pharmaceuticals: Offentliggørelse af storaktionærmeddelelser
Veloxis Pharmaceuticals: Offentliggørelse af storaktionærmeddelelser Selskabsmeddelelse nr. 4/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 15. januar 2020 Veloxis Pharmaceuticals: Offentliggørelse af storaktionærmeddelelser Veloxis Pharmaceuticals A/S (OMX: VELO) ("Veloxis") offentliggør hermed selskabets modtagelse af storaktionærmeddelelser i henhold til kapitel 7 i lovbekendtgørelse nr. 931 af 6. september 2019 Kapitalmarkedsloven ("Kapitalmarkedsloven"), med senere ændringer. Storaktionærmeddelelsern...
Veloxis Pharmaceuticals: Major Shareholder Notifications
Veloxis Pharmaceuticals: Major Shareholder Notifications Company Release no. 4/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 15 January 2020 Veloxis Pharmaceuticals: Major Shareholder Notifications Veloxis Pharmaceuticals A/S (OMX: VELO) ("Veloxis") hereby announces that it has received major shareholder notifications pursuant to chapter 7 of Consolidated act no. 931 of 06 September 2019 on Capital Markets, as amended (the "Capital Markets Act"). Pursuant to section 30 of the Capital Markets Act, these ma...
Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark Announces the Prel...
Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark Announces the Preliminary Result and Completion of its Public Tender Offer for the Shares and Warrants in Veloxis Pharmaceuticals Company Release no. 3/2020 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 15 January 2020 Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark Announces the Preliminary Result and Completion of its Public Tender Offer for the Shares and Warrants in Veloxis Pharmaceuticals On 25 November 2019, Asahi Kasei Pharma Denmark A/S ("Asahi Kasei Pharma Denmark") anno...
Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark offentliggør det ...
Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark offentliggør det foreløbige resultat af samt afslutningen på dets offentlige købstilbud på aktier og warrants i Veloxis Pharmaceuticals Selskabsmeddelelse nr. 3/2020 Til: NASDAQ Copenhagen A/S København, Danmark, 15. januar 2020 Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark offentliggør det foreløbige resultat af samt afslutningen på dets offentlige købstilbud på aktier og warrants i Veloxis Pharmaceuticals Asahi Kasei Pharma Denmark A/S ("Asahi Kasei Pharma Denmark") offentlig...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.